<img alt="" height="1" width="1" />
Regeneron-Bayer Drug Matches Lucentis at 2 Years in Fewer Doses
Bloomberg
Patients on Eylea gained an average of 7.6 letters on an eye chart after 96 weeks, compared with 7.9 for those on Lucentis, Regeneron and Bayer said today in a statement. The drugs were injected on an ...
Regeneron-Bayer Drug Matches Lucentis at 2 Years in Fewer DosesBusinessWeek
Bayer, Regeneron report encouraging data from Phase 3 AMD studiesPharmaceutical Business Review
Regeneron Reports 2 Year Phase 3 Study Results With EYLEA Injection In Wet AMDNASDAQ
The FINANCIAL -PR Newswire (press release) -ThirdAge
all 20 news articles &raquo;


More...